HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Purcell, H. Articles by Lewis, S. Search for Related Content PubMed Articles by Purcell, H. Articles by Lewis, S.

Postcode prescribing in psychiatry

Clozapine in an English county

School of Psychiatry & Behavioural Sciences, Department of Psychiatry, Withington Hospital, West Didsbury, Manchester M20 8LR

	Abstract

Top Abstract Introduction The study Findings Comment References

 
AIMS AND METHOD

We aimed to examine variations in clozapine prescribing in all 12 NHS trusts with catchment area mental health services in one English county, over a 2-year period. We tested a series of hypotheses to explain the variation in prescribing of clozapine.

RESULTS

A 34-fold variation between trusts in rates of clozapine provision was found after adjusting for measures of local population need. This variation did not change over the 2 years examined. It was not explained by differences in resource level.

CLINICAL IMPLICATIONS

The evidence base is strong for the effectiveness and likely cost-effectiveness of clozapine in severe schizophrenia. Our data indicate that variations in evidence-based clinical practice at the provider level led to the wide variation in clozapine prescribing.

	Introduction

Top Abstract Introduction The study Findings Comment References

 
Clozapine has been shown to be better in treating symptoms of schizophrenia than conventional antipsychotic drugs. Forty to 60 per cent of patients with refractory chronic schizophrenia will make clinically significant improvements with clozapine, based on high-quality evidence accepted by opinion leaders, policy-makers and purchasers of care (Wahlbeck et al, 1998). Clozapine, although essentially free of extrapyramidal side-effects, has a wide range of side-effects of its own, the most important being agranulocytosis. Although expensive, there is evidence to suggest that acquisition costs are recouped by future savings on in-patient care (Aitchison & Kerwin, 1997). In view of this evidence base 10 years after its UK licence, we aimed to examine patterns of clozapine prescribing in the NHS. We set out to explain any inequalities in prescribing either arising as variations in need or in provision, since analysis of such variations can reveal insights into policy and practice (Knapp, 1997).

	The study

Top Abstract Introduction The study Findings Comment References

 
We obtained prescribing data from all 12 NHS catchment area mental health provider units in an English county (total population 2 499 487), at three census dates: 1 April 1996, 1 November 1997 and 1 May 1998. Specialist tertiary care services such as forensic units were not included. We also obtained prescribing analysis and cost (PACT) information for the same timescale. PACT information was from the six health authorities that provided month-on-month expenditure details for other atypical antipsychotic drugs in primary care. This allowed for a longitudinal analysis over the 2-year period.

	Findings

Top Abstract Introduction The study Findings Comment References

 
Raw data for the first census date showed cross-sectional prescribing rates to range between two and 52 patients per trust. Table 1 details the clozapine prescribing figures by each trust on the three census dates.

To test whether these differences reflected variations in local population need, rates were corrected for population size and deprivation, using the Mental Illness Needs Index, shown to predict mental health service usage (Glover, 1998). Population size and need-adjusted prescribing data showed a 34-fold variation between trusts, as shown in Fig. 1. This confirmed that the reason for inequalities was not population need. Therefore, we tested a series of hypotheses concerning supply.

View larger version (19K): [in this window] [in a new window]   Fig. 1. Rates of clozapine prescribing in 12 provider units population and deprivation adjusted. [UNK], 1 April 1996; , 1 November 1997; , 1 May 1998

First, we ensured that no purchaser- or provider-imposed limits on availability were in force: prior to the availability of high-quality evidence, local policies had often restricted clozapine use. This was not the case at either of the last two census dates for any of the 12 units. Three trusts (C, D and K) used drug treatment algorithms for the prescribing of antipsychotic medication prior to and following the three census dates.

Second, we checked whether trusts with lower prescribing rates at census date 1 were merely at an earlier stage of evidence-based practice by comparing rates with those at census dates 2 and 3. We found no decrease in variation between trusts at each of the three time-points: in fact, an increase was evident, suggesting the gap was not closing (s.d.s=15.6, 16.0, 20.2).

Third, although overprescribing of clozapine is inherently unlikely given its cost and licensing restrictions, we tested whether this had occurred in the high prescribing trusts. Using Conley & Buchanan's (1997) accepted criteria for treatment resistance, the case records of the 31 patients most recently prescribed clozapine were examined in the highest prescribing trust (C). All of these cases were found to have conformed to these criteria, with persistent symptoms despite full trials of at least two different antipsychotic classes.

Fourth, we tested whether an alternative health technology was being provided for resistant schizophrenia in the low-prescribing trusts. Although the evidence base as yet gives formal support only to clozapine in resistant schizophrenia, there are emerging data for the effectiveness of cognitive-behavioural therapy (Tarrier et al, 1998) and good evidence for family interventions in preventing relapse (Mari & Streiner, 1994). On examination, the only four trusts to make available such services were the four highest, as opposed to the lowest, prescribers of clozapine. The newer atypical antipsychotic drugs introduced since clozapine may offer advantages over conventional drugs, although there is no good evidence that they are effective in treatment resistant schizophrenia (Tuunainen & Gilbody, 1999). Nonetheless, we tested whether they were being prescribed in lieu of clozapine in the low prescribing trusts. We found no evidence to support this. Rates of prescribing of this class of drug increased six-fold over the census interval (see Fig. 2), with rates of prescribing of the atypical antipsychotics showing in fact a positive correlation, r=0.4, rather than a negative, with rates for clozapine. Despite the place of new atypicals being less clear in schizophrenia management than clozapine, need adjusted variation between health authorities on the final census date was considerably less for new atypicals than for clozapine.

View larger version (12K): [in this window] [in a new window]   Fig. 2. Primary care prescribing of atypical antipsychotic medication

Our remaining hypothesis was that the variations in clozapine prescribing reflected variations in evidence-based clinical practice. We sought to test this by a case note review in a sample of the providers (Trusts A, C, E, F, G, H, I, J and L). This included all case notes of in-patients with an ICD-10 diagnosis of schizophrenia (World Health Organization, 1997; F20-F20.9) between 1 April 1996 and 31 March 1998. There were 1996 patients admitted during that period. Of the 777 case notes reviewed, 64% were male, 36% female and average age was 41 years. We checked for a putative marker of non-evidence-based practice: the prescribing of two or more antipsychotic drugs in parallel in the same patient. We found a 37% rate for such polypharmacy: in 33% there were two conventional drugs, 14% an atypical prescribed with a conventional drug and 0.4% were being prescribed two atypical antipsychotic drugs in parallel. The rates of polypharmacy between the trusts ranged from 28-51% of patients. The lowest prescribing trust for clozapine had the highest percentage of such polypharmacy.

	Comment

Top Abstract Introduction The study Findings Comment References

 
Access to appropriate care in the new NHS is intended to be "on the basis of need and need alone" (Secretary of State for Health, 1997). Doctors appear to have a statutory duty to prescribe what patients need, although the introduction of new drugs can be slow. Clozapine has been available in the NHS since 1990. Despite robust evidence about its unique efficacy and probable cost-effectiveness in severe schizophrenia, its availability to patients in the county studied was uneven, with no evidence of this changing over the 2-year period examined.

Recent media attention has focused on the role of financial constraints imposed by health authorities as a main source of the variance in availability of clozapine nationally. Our data suggest that differences in evidence-based clinical practice at the provider/prescriber level are the main source of variance. There is a need to strengthen the evidence base available to clinicians in order to improve and develop local prescribing strategies based on patient need. Without change at this level special funding strategies by health authorities to support clozapine will have little impact on its availability to patients.

	Acknowledgments

 
We would like to thank the trusts and health authorities for helping with data collection for the study and Dr Peter Elton, Director of Public Health, Wigan and Bolton Health Authority.

S.L. had the original idea for the study and obtained funding. H.P. was involved in data collection, with analysis and writing of the paper by both S.L. and H.P.

The study was supported by grants from Greater Manchester Health Authorities and the Stanley Foundation. No commercial funding was involved.

	References

Top Abstract Introduction The study Findings Comment References

 
AITCHISON, K. & KERWIN, R. (1997) Cost-effectiveness of clozapine. A UK clinic-based study. British Journal of Psychiatry, 171, 125-130.[Abstract/Free Full Text]

CONLEY, R. & BUCHANAN, R. (1997) Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin, 23, 663-674.

GLOVER, G. (1998) A needs index for mental health care. Social Psychiatry & Psychiatric Epidemiology, 88, 89-96.

KNAPP, M. (1997) Costs of schizophrenia. British Journal of Psychiatry, 171, 509-518.[Abstract/Free Full Text]

MARI, J. & STREINER, D. (1994) An overview of family interventions and relapse on schizophrenia: metaanalysis of research findings. Psychiatric Medicine, 24, 565-578.

SECRETARY OF STATE FOR HEALTH (1997) The New NHS: Modern, Dependable. London: Stationery Office.

TARRIER, N., YUUPOFF, L., KINNEY, C., et al (1998) Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. British Medical Journal, 317, 303-307.[Abstract/Free Full Text]

TUUNAINEN, A. & GILBODY, S. (1999) Clozapine vs newer ‘atypical’ neuroleptic medication for schizophrenia [protocol] Cochrane Review. In: The Cochrane Library, Issue 2. Oxford: Update Software.

WAHLBECK, K., CHEINE, M. & ESSALI, M. A. (1998) Clozapine v. ‘typical’ neuroleptic medication for schizophrenia. Cochrane Review. In: The Cochrane Library, Issue 2. Oxford: Update Software.

WORLD HEALTH ORGANIZATION (1997) The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization.

This article has been cited by other articles:

				J. Downs and M. Zinkler Clozapine: national review of postcode prescribing Psychiatr. Bull., October 1, 2007; 31(10): 384 - 387. [Abstract] [Full Text] [PDF]

				E. WHISKEY, T. WYKES, D. DUNCAN-McCONNELL, E. HAWORTH, N. WALSH, and S. HASTILOW Continuation of clozapine treatment: practice makes perfect Psychiatr. Bull., June 1, 2003; 27(6): 211 - 213. [Abstract] [Full Text] [PDF]

				K. P. HAYHURST, P. BROWN, and S. W. LEWIS Postcode prescribing for schizophrenia The British Journal of Psychiatry, April 1, 2003; 182(4): 281 - 283. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Purcell, H. Articles by Lewis, S. Search for Related Content PubMed Articles by Purcell, H. Articles by Lewis, S.